OMEICOS Therapeutics raises €17.0M Series C round

2 November 2018· Berlin, Germany· health, biotech, materials, b2b, deep_hardware

Proceeds will finance PROMISE-AF, a Phase II study on OMT-28 in patients with persistent atrial fibrillation, and continue expansion into ophthalmology

Investors

LeadForbion

Also participating

SMS groupVesalius Biocapital IIRemiges VenturesKfW GroupVC Fonds Technologie BerlinHigh-Tech Gründerfonds IIThe Falck Revocable Trust

About OMEICOS Therapeutics

Stage

Series C

Headquarters

Berlin, Germany

Founded

2013

Team Size

6–20

Sectors

healthbiotechmaterialsb2bdeep_hardware

https://www.omeicos.com/

Source: https://www.omeicos.com/news/press-releases/omeicos-therapeutics-closes-17m-series-c-financing-to-advance-lead-candidate-omt-28-towards-pivotal-trials-in-atrial-fibrillation/